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Abstract Cognitive deficits are prevalent in schizophre-
nia, and these deficits represent a disabling aspect of the
illness for which there are no current effective treatments.
Recent work has shown that sex hormone levels correlate
with brain activity and cognitive abilities differentially in
patients with schizophrenia relative to healthy control
groups. There is emerging evidence suggesting that
oestrogen-based therapies may be useful in reversing the
cognitive deficits associated with schizophrenia. To date,
the results from clinical trials using oestrogen-based ther-
apies to reverse cognitive impairment in schizophrenia
have shown that the selective oestrogen receptor modulator
raloxifene may be useful to improve attention, memory,
learning and the associated brain activity in chronically ill
men and women with schizophrenia or schizoaffective
disorder. While these findings of cognitive enhancement
with a selective oestrogen receptor modulator in people
with schizophrenia are encouraging, additional studies will
be required to replicate the initial results, assess the time
frame of treatment effects, identify biomarkers in subsets
of patients who may be more likely to optimally respond to
treatment, and identify a more precise mechanism of
action, which may include anti-inflammatory effects of
oestrogen-based treatments.
Key Points
Cognitive deficits are a disabling aspect of
schizophrenia, for which there are no treatments.
Oestrogen-based therapies for cognitive remediation
have support from animal and human studies.
The selective oestrogen receptor modulator
raloxifene has been shown to improve attention and
memory in men and women with schizophrenia.
1 Neurocognitive Deficits in Patients
with Schizophrenia, and Their Impact
Schizophrenia is a debilitating mental disorder, character-
ized by psychotic symptoms—which can be reduced in
severity via current antipsychotic treatments—and by
negative symptoms (such as inappropriate emotional
responses and lack of socialization) and cognitive deficits,
both of which are generally unresponsive to current treat-
ments. Cognitive deficits in schizophrenia are heteroge-
neous to the extent that most people with schizophrenia
display impairment across a wide range of cognitive
domains, whereas others may appear to display little to no
cognitive impairment, relative to healthy comparison
groups. The cognitive deficits associated with schizophre-
nia are disabling, such that these deficits are related to
functional impairment, which limits the ability of these
patients to attain educational goals and hold meaningful
employment [1].
In a relatively large sample of chronically ill patients,
we showed that people with schizophrenia could be clas-
sified into three distinct groups on the basis of their degree
& Thomas W. Weickert
t.weickert@unsw.edu.au
1 School of Psychiatry, University of New South Wales,
Sydney, NSW, Australia
2 Neuroscience Research Australia, Barker Street, Randwick,
Sydney, NSW 2031, Australia
3 Schizophrenia Research Institute, Sydney, NSW, Australia
CNS Drugs (2016) 30:125–133
DOI 10.1007/s40263-016-0312-0
of intellectual decline from a premorbid IQ estimate, and
these three groups displayed distinct patterns of cognitive
abilities versus deficits [2]. Approximately half of the
patients displayed a large ([10-point) reduction in their
current IQ estimates in relation to their premorbid IQ
estimates. These patients displayed impairment in the
cognitive domains of executive function and attention (i.e.
prefrontal cortex function) and memory (i.e. hippocampal
function); this group was referred to as the ‘deteriorated’
group. The other half of the patients did not display a large
decline in their intellectual abilities; however, approxi-
mately half of this half of patients (i.e. 25 % of the total
sample) displayed little to no change from low premorbid
IQ estimates (this group was referred to as the ‘compro-
mised’ group), while the other half (i.e. 25 % of the total
sample) appeared to display little to no change from high
premorbid IQ estimates (this group was referred to as the
‘preserved’ group). The compromised group displayed the
most widespread impairment across all cognitive domains
we assessed (including executive function, attention,
memory, language and visuospatial perceptual abilities).
Conversely, the preserved group displayed impairment
restricted to the cognitive domains of executive function
and attention when compared with an IQ-matched group of
healthy controls. However, both deteriorated and preserved
patients typically perform below their premorbid level of
cognitive function or potential, e.g. relative to their iden-
tical twin who is discordant for the illness [2, 3]; thus, the
optimal aim would be to restore cognitive abilities in these
patients to their previous potential and, to the extent pos-
sible, improve the cognitive function of those patients in
the compromised group. Since our original classification of
people with schizophrenia on the basis of their intellectual
decline from premorbid IQ estimates [2], the heterogeneity
of the cognitive deficits and the reliability and validity of
this classification mechanism of people with schizophrenia
into IQ-based subgroups have been demonstrated through
replication in both chronically ill [4–6] and first-episode
patient samples [7–9]. In a larger, independent replication
sample, we showed that all three of these IQ-based sub-
groups have room for cognitive improvement, with sig-
nificant difficulties in engaging socially and in attaining life
goals [5].
Human cognition includes a wide range of learning and
memory abilities, with only a portion of these abilities
being routinely assessed in studies of people with
schizophrenia; however, most studies have included some
measure of declarative memory. Declarative cognitive
processes typically involve the hippocampal formation and
are characterized by conscious awareness and effort [10].
Conversely, non-declarative cognitive processes are char-
acterized by automatization with no conscious awareness
of the process, and recruit cortical or subcortical brain
regions other than the hippocampus [10]. Non-declarative
cognitive processes are less commonly assessed in studies
of people with schizophrenia. Standardized cognitive bat-
teries that assess declarative cognitive processes typically
show marked performance deficits of 1–1.5 standard
deviations below the mean on average in people with
schizophrenia [2]; while studies of non-declarative cogni-
tive processes in people with schizophrenia initially
showed no non-declarative deficit [11], others now more
commonly report significant impairment in some non-
declarative cognitive processes [12]. In one form of non-
declarative cognitive processing called ‘probabilistic
association learning’, people gradually learn the probabil-
ity-based relationships between cues and outcomes. People
with schizophrenia display a reduced learning rate and an
overall performance deficit in probabilistic association
learning, relative to healthy controls [12]. In relation to the
neural substrate of probabilistic association learning,
healthy adults typically show decreased hippocampal
activity and increased striatal (caudate nucleus) activity
[13, 14], whereas people with schizophrenia show reduced
frontal–striatal activity in conjunction with an overall
performance deficit [15]. However, a proportion of people
with schizophrenia who are able to learn probabilistic
associations show reduced striatal (caudate nucleus)
activity and increased hippocampal formation activity [15].
Thus, some people with schizophrenia appear to learn the
probabilistic relationship using a different neural network
than that used by healthy controls, suggesting that there is
capacity for some form of neural compensation that may be
accessed to improve cognition in people with
schizophrenia.
In general, cognitive deficits in schizophrenia have been
associated with functional impairment, i.e. impairment of
the ability to perform at work or school [1]. Nuechterlein
and colleagues [16] showed that neurocognitive factors in
the three broad domains of working memory, attention/
perception, and verbal memory/processing speed predicted
52 % of the variance related to returning to school or work
after 9 months in first-episode schizophrenia patients. Hoe
and colleagues [17] showed that both neurocognition
(general mental processing) and social cognition (mental
processing that underlies social interactions) may be cau-
sally relevant to functional outcome in people with
schizophrenia. Harvey and colleagues [18] showed that
many people with schizophrenia display impairment across
multiple functional domains, and they tend to remain
functionally impaired throughout their life. Thus, identi-
fying treatments—pharmacological or otherwise—that will
restore cognitive function in people with schizophrenia
should confer a substantial benefit on their functional
abilities, in addition to their quality of life. However,
although there have been numerous studies of
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pharmacological agents aimed at improving cognition in
schizophrenia, there has been a paucity of studies showing
reversal of cognitive deficits with pharmacological treat-
ments in people with schizophrenia.
To date, the findings from studies of pharmaceutical
treatments for remediation of cognitive deficits in people
with schizophrenia have been mixed, with some studies
showing improvement with treatment and others generally
showing no significant improvement, relative to placebo.
Using an alpha-7 nicotinic receptor agonist, Keefe and
colleagues [19] showed significant improvement in per-
formance on the CogState battery [20] with relatively small
effect sizes (Cohen’s d = 0.26), but no significant
improvement on the Measurement And Treatment
Research to Improve Cognition in Schizophrenia
(MATRICS) battery [21]. Although administration of a
generalized attention-enhancing agent (modafinil) with an
uncertain mechanism of action elicited enhanced cortical
gamma-range oscillatory power [22], other studies [23]
failed to find significant differences between modafinil
treatment and placebo on assays of trained tasks and cog-
nitive measures from the MATRICS battery. Given that
cognitive deficits are related to functional impairment,
which prevents full recovery, and that no effective phar-
macological treatments for cognitive deficits are presently
available, there remains an urgent need to identify novel
pharmacological treatments to reverse cognitive deficits in
people with schizophrenia.
2 Rationale for Investigating Oestrogenic
Therapies to Treat Cognitive Deficits
in Schizophrenia
There is recent evidence to suggest that cognitive deficits in
people with schizophrenia may benefit from treatment with
oestrogen-based therapies. On the basis of correlational
studies, two independent studies [24, 25] showed signifi-
cant positive relationships between circulating oestrogen
levels and cognitive performance in women with
schizophrenia. Using functional magnetic resonance
imaging (fMRI), Mendrek and colleagues [26] showed a
significant positive correlation between sex hormone levels
and brain activity in healthy men and women with
schizophrenia during a spatial rotation test, but there was
no such relationship in healthy women and men with
schizophrenia.
There is also a large and fairly well developed knowl-
edge base demonstrating that oestrogen promotes neu-
rotrophin synthesis, protects the brain against stress and
inflammation, and has pro-cognitive effects. While the
molecular substrates of cognitive deficits in schizophrenia
are largely unknown, some evidence suggests that
hormonal–inflammation interactions may have a modula-
tory role in cognitive protection–impairment. We reported
an increased frequency of markers of inflammation (ele-
vated cytokine expression) in the brains of people with
schizophrenia relative to control groups from two inde-
pendent cohorts [27, 28]. Furthermore, we also recently
showed significant inverse relationships of peripheral
cytokine levels to a specific neurocognitive ability
(i.e. language as measured by verbal fluency) and the brain
volume of Broca’s area (which is a brain region related to
speech production) in people with schizophrenia [29],
suggesting a link between increased inflammation and poor
cognition.
Animal studies have shown that increased cytokine
levels may negatively impact cognition. In rodents, dam
exposure to the cytokines interleukin-1b (IL-1b) and
tumour necrosis factor alpha (TNF-a) reduced neuronal
dendrites and dendritic length in pups [30]. Stress can
increase levels of IL-1b in the hippocampus [31], and IL-
1b can inhibit adult hippocampal neurogenesis, which can
be reversed by blockade of IL-1b [32]. Peripheral and
central IL-1b administration elicits anhedonia and deficits
in social interaction and memory [32, 33], which are sim-
ilar to behavioural deficits that occur in schizophrenia.
Thus, treatments that are capable of reducing cytokine
levels may also reverse cognitive impairment in
schizophrenia. Interestingly, oestrogen has been shown to
have anti-inflammatory effects by reducing cytokine levels
[34–39].
Given the negative effects of cytokines on cognition, the
reduced cytokine levels elicited by oestrogen [34–39] may
concurrently improve cognition. However, treatments tar-
geting inflammation in schizophrenia have also shown
mixed results. In schizophrenia trials, the antibiotic
minocycline improved executive (prefrontal cortex) func-
tion [40]; however, aspirin did not improve cognition [41].
Importantly, it should be noted that these studies did not
stratify patients on the basis of increased/decreased cyto-
kine levels prior to administration of the anti-inflammatory
agents; thus, the effect of the anti-inflammatory agent in
these studies may have been diluted by inclusion of
patients both with and without inflammation.
Sex hormones in general, and oestrogen in particular,
may have protective effects in relation to schizophrenia,
given that a slightly smaller proportion of females develop
schizophrenia, relative to males (2:3), and that in females
who do develop schizophrenia, their symptom severity is
greater when oestrogen levels are low, such as at times of
the oestrous cycle when oestrogen is low, or after meno-
pause [42]. Testosterone can also be converted to oestrogen
in the brain by the aromatase enzyme; thus, oestrogen
receptor binding and oestrogen action in the brain can also
be relevant in men as well as in women.
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In a series of studies, we showed differential relation-
ships between cognitive function, brain activity and cir-
culating testosterone levels in healthy men and men with
schizophrenia. We showed that circulating testosterone
levels explain 13–21 % of the unique variance in relation
to verbal memory, working memory and processing speed
in chronically ill men with schizophrenia, whereas no such
relationship exists in healthy men [43]. Additionally, in
men with schizophrenia, circulating testosterone levels
were inversely related to prefrontal cortex activity during
inhibition of emotional words [44] and positively related to
inferior frontal cortex activity during recognition of angry
faces [45], whereas no such relationship existed in healthy
men in these studies. Conversely, while healthy men dis-
played a positive relationship between circulating testos-
terone levels and brain activity in the ventral striatum
during positive prediction error (a measure of unexpected
reward) and an inverse relationship between circulating
testosterone levels and ventral striatum activity during
negative prediction error (a measure of unexpected omis-
sion of reward), men with schizophrenia showed no such
relationships between circulating testosterone levels and
ventral striatal activity [46]. Circulating testosterone levels
in men with schizophrenia in these studies did not differ
significantly from those in healthy men. Thus, variation in
normal testosterone levels may be capable of modulating
cognitive abilities and related brain activity differently in
men with schizophrenia versus healthy men, and these
relationships appear to be dependent on task demands and
the brain region (e.g. cortical versus subcortical) typically
relevant to the task. Additionally, as noted above, these sex
steroid relationships may be working through either the
oestrogen receptor in the brains of women with
schizophrenia or through both the androgen receptor and/or
the oestrogen receptor in the brains of men with
schizophrenia.
It is important to consider that not only could the cir-
culating levels of sex hormones be altered in schizophrenia,
for which the evidence is mixed [43, 47–50], but also it
may be that the brain response to these hormones is
attenuated. Indeed, from a molecular brain perspective, we
found that men and women with schizophrenia displayed
reduced messenger RNA (mRNA) levels of oestrogen
receptor alpha (ESR-1) in the hippocampus [51] and
decreased frequencies of wild-type ESR-1 mRNA in the
prefrontal cortex [52], which would be indicative of an
attenuated oestrogen response. Using an in vitro luciferase
assay to monitor gene expression, we confirmed that the
altered form of the oestrogen receptor, which is found more
often in the brains of people with schizophrenia, works as a
dominant negative, antagonising/blocking the activity of
wild-type ER [52]. Thus, not only could low blood levels
of oestrogen contribute to cognitive deficits, but also the
presence of altered oestrogen receptors in the hippocampus
and cortex could also likely contribute to the cognitive
deficits that are observed [51, 52]. Therefore, stimulation of
oestrogen receptors in the brains of men and women with
schizophrenia may improve or restore cognitive ability.
There is already a precedent for treatment with addi-
tional oestrogen to benefit memory and attention in both
animals and in humans. First, we will consider a few
examples from work in animals. Following early studies
suggesting that oestrogen can influence spine density in the
hippocampus [53, 54], a number of studies focused on the
influence of oestrogen in hippocampal-based spatial
memory, and these studies found that oestrogen is gener-
ally beneficial to spatial working memory in young and
aged female rats [55–58]. Oestrogen also enhances non-
spatial memory, including associative memory [59], non-
spatial working memory [60] and episodic memory, such
as object placement and recognition [61]. However, other
studies have suggested that oestrogen can impair perfor-
mance in spatial memory tasks [62, 63]. Oestrogen
administration can also enhance visuospatial attention in
young ovariectomised and aged female rats [64] and
monkeys [65], but may not influence reaction time in
monkeys [65]. Therefore, oestrogen effects may depend on
the dose, duration and timing of oestrogen administration,
as well as on the context and specific cognitive domain
used to perform the task.
In relation to humans, there is also mixed evidence in
favour of oestrogen-based treatments for cognitive
impairment in individuals of advanced age. While some
studies of older, postmenopausal women demonstrated
cognitive enhancement with oestrogen replacement therapy
[66], other work failed to demonstrate restoration of cog-
nitive deficits in postmenopausal women with dementia
[67]. It is thought that the lack of a beneficial effect of
oestrogen on aged brain function may have to do with the
timing of oestrogen replacement (with longer delays after
menopause being less effective) or the effects of comor-
bidity from hypertension and/or diabetes in older adults
[68, 69]. In addition to the mixed results of oestrogen
replacement therapy to reverse cognitive deficits in older
women, oestrogen replacement therapy alone is associated
with increased breast and uterine cancer in females and
feminizing effects in males. Thus, other oestrogen-based
treatments targeting the brain that would not have the
general adverse events common to direct oestrogen therapy
would be optimal.
The selective oestrogen receptor modulator (SERM)
raloxifene has antagonist effects on the oestrogen receptor
in the breast and uterus without feminizing effects in males
[70], and has agonistic effects on the oestrogen receptor in
bone and in brain tissue [71]. Preclinical studies provided
evidence that raloxifene acts in an oestrogen-like manner in
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the mammalian brain, e.g. raloxifene mimics the effects of
oestrogen on various parameters of dopamine and serotonin
neurotransmission [71–74]. Importantly, raloxifene has
been shown to prevent age-related cognitive decline in
brain activity during memory tests in healthy older men
[75, 76]. In postmenopausal women, raloxifene treatment
at 120 mg daily, but not at 60 mg daily, reduced the age-
related decline in attention and verbal memory, and
reduced the risk of developing mild cognitive impairment
[77]. Thus, raloxifene is an oestrogen-based pharmaco-
logical agent with potential to reverse cognitive deficits in
men and women with schizophrenia. However, the exact
neurobiological mechanisms by which raloxifene acts in
the human brain regions integral to cognition (including the
hippocampus and cerebral cortex) have not been fully
elucidated to date.
3 Clinical Findings from Studies of Oestrogen-
Based Treatment Trials to Reverse Cognitive
Deficits in Schizophrenia
There is mixed evidence regarding the effectiveness of
using oestrogen-based treatments to reverse the cognitive
deficits associated with schizophrenia (see Table 1). One
study reported specific improvement in speech compre-
hension with administration of 17b-oestradiol in women
with schizophrenia [78]. However, using a transdermal
oestradiol patch therapy, Kulkarni and colleagues [79]
failed to show improvement in cognitive abilities in women
with schizophrenia as measured by the Repeatable Battery
for the Assessment of Neuropsychological Status [80],
although those women with schizophrenia did demonstrate
significant reductions in psychotic symptoms, relative to
use of placebo. Similarly, administration of dehy-
droepiandrosterone (DHEA), an intermediate in the syn-
thesis of sex steroids, produced mixed results, with some
studies showing improvement in attention and skill learn-
ing [81, 82], while others reported no significant benefits of
DHEA treatment in schizophrenia [83, 84]. While the
results of studies using oestrogen and DHEA to improve
cognition in schizophrenia appear to be mixed, other
studies using oestrogen-related therapies (specifically the
SERM raloxifene), have provided more consistent results
to date, although the number of studies using raloxifene to
treat cognitive deficits in schizophrenia is small.
Oestrogen-based treatment (specifically the SERM
raloxifene) has been shown to reduce positive symptoms
(including thought derailment/disorder) and generalized
anxiety [85, 86], all of which may be putatively elicited/
exacerbated by trauma, prenatal infection and/or substance
abuse/dependence. Huerta-Ramos and colleagues [87]
showed significant improvements in executive function and
memory with administration of 60 mg of raloxifene daily
for 12 weeks in a small sample of between 16 and 26
postmenopausal women with schizophrenia. More recently,
in a larger randomized, double-blind, placebo-controlled,
cross-over study of 98 adult men and women with
schizophrenia or schizoaffective disorder (mean age
35 years) we showed significant improvements (with
medium to large effect sizes) in attention and memory with
administration of 120 mg of raloxifene daily for 6 weeks
[88]. Additionally, in a subset of patients from our ralox-
ifene trial, who received fMRI, 19 men and women with
schizophrenia or schizoaffective disorder displayed sig-
nificant improvement in a better probabilistic association
learning test (a test of non-declarative cognitive processes)
in conjunction with increased hippocampal activity
Table 1 Summary of cognitive outcomes from oestrogen-based treatment trials in schizophrenia
Study, year Treatment Sample Outcome
Bergemann et al. [78], 2008 Oestradiol Women with schizophrenia Significant speech comprehension improvement
Kulkarni et al. [79], 2015 Oestradiol Women with schizophrenia No significant cognitive improvement
Ritsner et al. [82], 2006 DHEA Men and women with
schizophrenia
Significant attention and skill learning improvement
Ritsner et al. [83], 2010 DHEA Men and women with
schizophrenia
DHEA negative predictor of cognition
Strous et al. [84], 2007 DHEA Men and women with
schizophrenia
No significant cognitive improvement
Huerta-Ramos et al. [87], 2014 Raloxifene Women with schizophrenia Significant executive function and memory improvement
Weickert et al. [88], 2015 Raloxifene Men and women with
schizophrenia
Significant memory and attention improvement
Kindler et al. [89], 2015 Raloxifene Men and women with
schizophrenia
Significant improvement in learning and increased brain
activity
DHEA dehydroepiandrosterone
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following administration of 120 mg of raloxifene daily for
6 weeks [89]. Thus, while increased hippocampal activity
is related to poor performance on traditional cognitive tests
of declarative learning and memory in people with
schizophrenia [90], on a test of striatal-based non-declar-
ative probabilistic association learning, increased hip-
pocampal activity was related to increased learning, which
was consistent with the findings of previous work in
patients showing increased hippocampal activity concur-
rent with better probabilistic association learning [15, 89].
This finding suggests that the human hippocampus repre-
sents a neural substrate through which oestrogen receptor
stimulation may bring about cognitive benefits in people
with schizophrenia, which is consistent with the hip-
pocampus being enriched in oestrogen receptors and being
responsive to sex hormones [91, 92]. However, the exact
mechanism by which SERMs, such as raloxifene, may
work to produce cognitive benefits is presently unknown,
and the brain regions potentially benefiting from SERMs,
such as raloxifene, may not be restricted to the hip-
pocampus. Additionally, we found that raloxifene admin-
istered at 120 mg daily as an adjunct to antipsychotics in
men and women with schizophrenia was well tolerated,
with no serious adverse events related to the treatment, and
the compliance rate was high. This suggests that treatment
with SERMs, and raloxifene in particular, may have real
clinical potential and warrants further study of these agents
as a treatment for cognitive deficits in schizophrenia.
However, while early evidence suggests that raloxifene
may be useful to improve attention, memory, learning and
the associated brain activity in chronically ill men and
women with schizophrenia, this inference is based on a
limited number of randomized controlled clinical trials that
recruited different cohorts of patients in terms of age and
gender ratios, administered different doses and assessed a
limited range of cognitive abilities.
4 Conclusions
Cognitive deficits are common in schizophrenia, and these
cognitive deficits are related to functional impairment,
which represents a major obstacle to full recovery. At
present, no effective pharmacological treatments are
available to reverse the cognitive deficits associated with
schizophrenia. However, there is evidence that supports a
role of sex hormones and oestrogen in cognitive processing
in people with schizophrenia, and some randomized, con-
trolled trials of oestrogen-based treatments have generally
shown promising effects (with substantial effect sizes)
towards reversing some of the debilitating cognitive defi-
cits in both men and women with schizophrenia and
schizoaffective disorder. While many studies have focused
on determining the neuroprotective actions of oestrogens,
far less is known about SERMs’ (specifically raloxifene’s)
mechanism of action in the brain. There is also some evi-
dence indicating that SERMs and oestradiol act differently
[93]. While the initial clinical studies provide hope, iden-
tifying the exact mechanism through which SERMs, such
as raloxifene, may work (e.g. possibly through reducing
inflammation) to bring about reversal of cognitive deficits
in schizophrenia may provide even more effective treat-
ments for schizophrenia.
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